RU2805492C1 - Method for correction of post-prandial glycemia - Google Patents

Abstract

FIELD: medicine; endocrinology.

SUBSTANCE: invention can be used in the correction of postprandial glycemia. The method includes the use of a monocomponent herbal drug with hypoglycemic activity. As a monocomponent medicinal herbal preparation, an aqueous infusion of the blue cyanosis herb Polemonii caerulei herba is used in the ratio of 1 g of dried plant material with a moisture content of 11% per 10 ml of extractant - purified water. The infusion is administered orally at a dose of 120 mg/kg of body weight based on the dry residue 60 minutes before the glucose load.

EFFECT: use of the invention makes it possible to increase the efficiency of correction of postprandial glycemia during a glucose load.

1 cl, 1 dwg, 1 ex

Description

According to WHO, diabetes mellitus (DM) occurs in all countries of the world, regardless of region, including in rural areas of low- and middle-income countries. The total number of patients with diabetes in the Russian Federation registered at the dispensary as of 01/01/2021, according to the register, was 4,799,552 (3.23% of the population of the Russian Federation), of which: type 1 diabetes mellitus (T1DM - 5.5% (265 .4 thousand), type 2 diabetes mellitus (DM2) - 92.5% (4.43 million), other types of diabetes - 2.0% (99.3 thousand). The dynamics of prevalence was for T1DM 168.7 → 180.9/100 thousand population, with T2DM 2709→3022/100 thousand population; incidence - with T1DM 10.5→7.7/100 thousand population, with T2DM 219.6→154.2/100 thousand. [Diagnosis and management of type 2 diabetes, URL: https://apps.who.int/irisbitstream/handle/10665/331710/WHO-UCN-NCD-20.1 -rus.pdf. Global report on diabetes, URL: https://apps.who.int/iris/bitstream/handle/10665/275388/9789244565254-rus.pdf; Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M. A. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the diabetes registry data as of 01/01/2021. Diabetes mellitus. 2021; 24(3): 204-221. URL: https://doi.org/10.14341/DM12759].

A common consequence of uncontrolled diabetes is hyperglycemia - elevated levels of glucose in the blood, which over time leads to serious damage to many body systems, especially nerves and blood vessels [ https://www.who.int/ru/news-room/fact-sheets/ detail/diabetes].

Currently, the number of cases of diabetes is growing rapidly. In this regard, an urgent problem in pharmacy and medicine is the development of new effective medicines for the treatment of diabetes mellitus, including herbal remedies [Use of natural herbal ingredients in the treatment of patients with diabetes mellitus // Medicine. Sociology. Philosophy. Applied research. 2020. No. 3. URL: https://cyberlenirika.ru/article/n/ispolzovanie-naturalnyh-rastitelnvh-ingredientov-pri-lechenii-bolnvh-saharnym-diabetoml. It is known that improving glycemic control significantly reduces the incidence of macroangiopathic complications in patients with type 1 or 2 diabetes, while reducing postprandial (after meals) plasma glucose has a leading role and is no less important for achieving target levels of glycated hemoglobin [Ametov A. S., Melnik A.V. Management of diabetes mellitus: the role of postprandial hyperglycemia and the possibility of its correction. RMJ. 2007. No. 27 P. 2053, Russian Medical Journal URL: http://www.rmj.ru/articles/endokrinologiya/Upravlenie_sahamym_diabetom_roly_postprandialynoy_giperglikemii_i_vozmoghnosti_ee_korrekcii/#ixzz7kz9sLeh 1].

To control glycemic levels in patients with type 2 diabetes mellitus, various hypoglycemic agents are used, their main groups are: biguanides; thiazolidinediones; sulfonylurea derivatives; glinides; α-glucosidase inhibitors; incretins: dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) and glucagon-like peptide-1 receptor agonists (arGLP-1), as well as a new group of gliflozins - sodium-glucose cotransporter type 2 inhibitors (SGLT-2, synonym SGLT2). One of the main typical disadvantages of many synthetic hypoglycemic drugs is a large list of contraindications (including renal and liver failure, severe decompensation of diabetes, pregnancy, lactation), side effects, incl. gastrointestinal discomfort, the risk of hypoglycemic conditions, and also, for example, for iNGLT-2, the risk of a serious adverse reaction - ketoacidosis is reported [Bukatina T.M., Kazakov A.S., Velts N.Yu., Darmostukova M.A. ., Kolesnikova E.Yu., Alyautdin R.N., Romanov B.K. Sodium-glucose cotransporter 2 inhibitors: risk of ketoacidosis // Safety and risk of pharmacotherapy. 2016. No. 2. URL: https://cyberleninka.ru/article/ri/ingibitorv-natriy-glyukoznogo-kotransportera-2-risk-ketoatsidoza]. In addition, many modern hypoglycemic drugs, for example the drug exenatide, are expensive [https://www.eapteka.ru/goods/drugs/diabet/gipoglikemicheskie_preparaty/prepara_ty_usilivayushchie vydelenie_insulina_podzheludochnoy_zhelezoy/baeta_eli_lilli/_?utm_referrer=https%3a%2f% 2fVandex.ru %2f].

In contrast to synthetic oral hypoglycemic agents, the list of known herbal preparations with hypoglycemic action for use in diabetes mellitus is very small. According to the State Register of Medicines [https://grls.rosminzdrav.ru/grls.aspx?s=&m=mnn], the number of medicinal herbal preparations with a hypoglycemic effect is only 4 items, all of them are represented by medicinal herbal raw materials for infusion - blueberry shoots, common bean leaves, collections Arfazetin and Arfazetin-E) [https://grls.rosminzdrav.ru/grls._aspx?s=&m=mnn"|. Known registered collections Arfazetin and Arfazetin-E [https:/ /www.rlsnet.ru/drugs/arfazetin-e-24565] contain rhizomes and roots of Eleutherococcus, Manchurian aralia, rhizomes with roots of zamanika, and therefore have disadvantages associated with limited use in the elderly, with hypertension , insomnia, increased excitability, and also due to the tonic effect, it is undesirable to use infusions from the above mixtures in the evening.

Currently, a number of compositions with hypoglycemic action have been proposed and patented in the Russian Federation, including components from medicinal plant raw materials, for example, a collection with hypoglycemic activity containing dandelion roots, yarrow herb, nettle leaves, plantain leaves, strawberry leaves, lingonberry leaves, fruit leaves common beans with their equal ratio [Patent No. 2666398 C1 Russian Federation, IPC A61K 36/73, A61K 36/185, A61K 36/28. Collection with hypoglycemic activity: No. 2017136331: application. 10/13/2017: publ. 09/07/2018 / Yu.F. Glukhov, A.R. Akhmetyanova, R.R. Fayzullina, N.V. Kudashkina. - EDN MRRVOE.]; antidiabetic collection of medicinal plants containing plantain, rowan fruits, dandelion leaf, nettle leaf, additionally contains elderberry flowers, bean leaves, linden flowers, centaury herb, parsley herb, raspberry berries, blueberries, blackberries, flax seed [Patent No. 2480231 C2 Russian Federation, MPK A61K 36/73, A61K 36/68, A61K 36/185. Antidiabetic collection of medicinal plants: No. 2010145936/15: application. 11/10/2010: publ. 04/27/2013 / R.D. Kusova, A.G. Sidakov, G.R. Gadzhinov; applicant State educational institution of higher professional education "North Ossetian State University named after Kosta Levanovich Khetagurov". - EDN OVQLTW https://www.freepatent.ru/patents/2480231]; antidiabetic collection containing fruit leaves of common beans, galega (goat's rue) herb, motherwort herb, nettle leaves and green tea leaves in equal proportions [Patent No. 2284829 C2 Russian Federation, IPC A61K 36/82, A61K 36/185, A61K 36 /48. Antidiabetic collection: No. 2004136941/15: application. 12/16/2004: publ. 10.10.2006 / I.V. Pshukova, Yu.A. Ogurtsov, N.V. Prudent, A.M. Domunyan; applicant Pyatigorsk State Pharmaceutical Academy. - EDN HXBKRB. https://vandex.ru/patents/doc/RU2284829C2 200610101: a product with hypoglycemic activity, containing shoots of blueberry, knotweed grass, rhizomes and roots of elecampane, leaves of stinging nettle, goat willow bark [Patent No. 2141841 C1 Russian Federation , MPK A61K 36/76, A61K 36/185, A61K 36/28. Method for obtaining a product with hypoglycemic activity: No. 99105540/14: application. 03/11/1999: publ. 11/27/1999 / E. V. Petrov, 3. M. Zanabadarova, M. M. Aryaeva [and others]; applicant Institute of General and Experimental Biology, Siberian Branch of the Russian Academy of Sciences. - EDN KGQIQX. https://vandex.ru/patents/doc/RU 2141841 C1 199911271: hypoglycemic collection from medicinal plants, containing shoots of blueberries, common beans, galega officinalis herb, knotweed herb, roots of burdock, cinnamon rose hips [Kutovaya A.M. , Martynchik I.A., Trumpe T.E., Ferubko E.V., Davydova V.N. Development and experimental study of a hypoglycemic collection from medicinal plants. Development and registration of medicines. 2018; (4): 78-81]. As a disadvantage of the listed compositions from plant raw materials, it should be noted, first of all, that many of the listed plant species are not pharmacopoeial [State Pharmacopoeia of the Russian Federation: in 4 volumes, 14th ed. Moscow. 2018. URL: http://femb.m/femb/pharmacopea.php], do not have developed methods for assessing the content of biologically active substances (BAS), which, therefore, causes difficulties in standardizing the finished product. The next disadvantage is that the presented phytocompositions contain plant materials that exhibit serious undesirable effects (nettle, yarrow, galega officinalis, etc.), for example, stinging nettle leaves exhibit hemostatic properties associated with the content of vitamin K, which may increase the risk development of thrombosis (hypercoagulation) [https://www.rlsnet.ru/drugs/krapivv-listva-44331, galega officinalis contains alkaloids, incl. toxic compound galegin [Paliy A.E., Logvinenko I.E., Logvinenko L.A., Grebennikova O.A., Vinogradov B.A. Biologically active substances of Galega officinalis L. // Plant biology and horticulture: theory, innovations. 2011. No. 133. URL: https://cvberleninka.ru/article/n/biologicheski-aktivnve-veschestva-galegi-lekarstvennoy-galega-officinalis-11, which, in addition to the hypoglycemic effect, exhibits the ability to inhibit intestinal motility and constrict blood vessels. As a last and important drawback, we can note the inaccessibility of some plants (for example, galega officinalis).

It is known to use the purified amount of saponins from the rhizomes and roots of blue cyanosis (Polemonium coeruleum L.) as a hypoglycemic agent [Evaluation of the hypoglycemic effect of the blue cyanosis preparation / A. A. Sorokina, A.A. Maltseva, T.A. Brezhnev, A.I. Slivkin // Pharmacy. - 2010. - No. 2. - pp. 18-20; Maltseva, A.A. Study of the complex of biologically active substances of the plant Polemonium coeruleum L: specialty 14.04.02 "Pharmaceutical chemistry, pharmacognosy": dissertation for the degree of candidate of pharmaceutical sciences / Maltseva Alevtina Alekseevna. - Moscow, 2011. -128 p. - EDN QFJVBR]. The disadvantage of the described product is the labor-intensive process of obtaining the amount of saponins, loss of the main substance as a result of purification, time and energy consumption, and the need to use special equipment.

The closest thing to the present invention is the use of liquid extracts of rhizomes with roots and blue cyanosis herb to provide a hypoglycemic effect. It has been shown that the liquid extract of cyanosis herb has the greatest hypoglycemic activity, exhibiting its effect 60 minutes after a single intraperitoneal injection and providing a decrease in glycemia over the next 1.5 hours [Maltseva, A.A. Study of the complex of biologically active substances of the plant Polemonium coeruleum L.: specialty 14.04.02 "Pharmaceutical chemistry, pharmacognosy": dissertation for the scientific degree of candidate of pharmaceutical sciences / Maltseva Alevtina Alekseevna. - Moscow, 2011. - 128 p. - EDN QFJVBR.].

It is known that blue sinyuhi grows on the territory of the Russian Federation, is a plant included in the State Fund of the Russian Federation, FS.2.5.0039.15 Blue sinyuhi rhizomes with roots [https://pharmacopoeia.ru/fs-2-5-0039-15-sinyuhi- goluboi-kornevishha-s-kornyamil, approved for use in medical practice, has a secure raw material base from wild and cultivated raw materials. Herbal medicinal preparations containing rhizomes with roots of blue cyanosis are used as a sedative and expectorant [http://horst-altay.ru/katalog/monotravy/item/149-sinyukha-golubaya-koren]. Blue cyanosis grass is used as a biologically active food additive, for example, the dietary supplement “Blue cyanosis grass” (Horst Company LLC, Russia) [http://horst-altav.ru/katalog/monotravy/item/221 -sinvukha- golubaya-trava].

The use of blue cyanosis herb infusion as a monocomponent hypoglycemic agent for the correction of postprandial glycemia is not known.

At the same time, various groups of biologically active substances included in the blue cyanosis herb can probably provide a hypoglycemic effect. Blue cyanosis grass contains mainly triterpene pentacyclic saponins, flavonoids and organic acids; it is known that these compounds in combination can provide sedative and antioxidant effects. It is known that saponins of other plants (Manchurian aralia, common beet) exhibit hypoglycemic activity [Saponins of plants Polemonium coeruleum L. and beta vulgaris L., characteristics of production, comparative assessment of hypoglycemic activity / S.A. Boeva, T.A. Brezhnev, A.A. Maltseva [and others] // Bulletin of Voronezh State University. Series: Chemistry. Biology. Pharmacy. - 2007. - No. 1. - pp. 139-141. - EDN KWHQVD.], probably stimulating the release of insulin and thereby facilitating the penetration of glucose into the cells of the body [Eremenko Rimma Fuatovna, Maloshtan Lyudmila Nikolaevna, Yatsenko Elena Yuryevna Experimental study of the hypoglycemic activity of an extract from the grass alfalfa // Kazan medical journal.. 2014 No. 4. URL: https://cyberleninka.ru/article/n/eksperimentalnoe-issledovanie-gipoglikemicheskoy-aktivnosti-ekstrakta-iz-travy-lvutserny-posevnoy: Povydysh M.N., Luzhanin V.G., Ivkin D.Yu., Belousov M.V., Yakovlev G.P. Prospects for the use of phytotherapeutic agents for disorders of fat and carbohydrate metabolism. Development and registration of medicines. 2018; (3):130-135].

It is also known that flavonoids, namely rutin, are able to reduce the absorption of glucose from the small intestine by inhibiting α-glucosidases and alpha-amylase, which prevents a sharp increase in blood glucose levels after meals. Rutin's reduction in blood glucose levels can also be achieved by stimulating insulin secretion by beta cells and increasing glucose uptake into skeletal muscle and adipose tissue. Histopathological studies in animal models of diabetes have shown that rutin improves the histoarchitecture of the islets of Langerhans and suppresses glucolipotoxicity in pancreatic beta cells [https://vandex.ru/patents/doc/RU 2773856 C1 20220614, Ghorbani A. Mechanisms of antidiabetic effects of flavonoid rutin // Biomedicine & Pharmacotherapy. - 2017. - Vol.96. - p. 305-312.]

The disadvantages of the above proposed hypoglycemic agents containing extracts of blue cyanosis from medicinal plant materials are the method of administration into the body that is not optimal for clinical practice (intraperitoneal), as well as the labor costs in obtaining liquid extracts and the method of obtaining the extract - the use of ethyl alcohol 70% as an extractant, as a result, not the entire amount of triterpene saponins is extracted, given that plant materials contain both water- and alcohol-soluble saponins. Ethyl alcohol helps extract related compounds, for example, chlorophyll. Also, alcohol extracts have some restrictions in use (childhood and old age, driving vehicles, inability to use alcohol-containing drugs due to concomitant therapy, etc.).

Thus, there is a known mention of the hypoglycemic effect of the purified sum of saponins from the rhizomes with roots of blue cyanosis and liquid extracts of rhizomes with roots and herb blue cyanosis. However, the use of an infusion of blue cyanosis herb for the correction of postprandial glycemia when administered orally is currently not known, which characterizes the scientific novelty and inventive step of the present invention.

The purpose of the present invention is to develop a method for correcting postprandial glycemia, characterized by the use of an oral monocomponent hypoglycemic agent of plant origin, which uses an infusion of the blue cyanosis herb (Polemonii caerulei herba).

The proposed remedy, an infusion of blue cyanosis herb, obtained by a standard method, can be used to correct postprandial glycemia, which can be clinically significant for glycemic control in the prevention and treatment of type 2 diabetes. The components of the proposed product (blue cyanosis grass), according to known data, are distinguished by a wide range of biological activity, low toxicity and, based on the composition of known components (saponins, rutin, flavonoids), can help increase tolerance to carbohydrates (see above).

The technical result consists in a pronounced hypoglycemic effect of an aqueous infusion of blue cyanosis herb with its single oral administration at a dose of 120 mg/kg body weight, manifested by a decrease in postprandial glycemia at a glucose load of at least 1.5-2 times compared with the control group, starting no later than 1.5 hours after administration of the infusion, lasting at least 2 hours and exceeding in severity the effect of the well-known hypoglycemic herbal drug Arfazetin by 1.5-2 times.

The technical result is achieved by the fact that in the method for correcting postprandial glycemia, including the use of a monocomponent medicinal herbal preparation with hypoglycemic activity, according to the invention, an aqueous infusion of blue cyanosis herb Polemonii caerulei herba is used as a monocomponent medicinal herbal preparation in the ratio of 1 g of air-dried plant material with a moisture content of 11% per 10 ml of extractant - purified water, the infusion is administered orally at a dose based on the dry residue of the infusion of 120 mg of the dry residue of the infusion / kg of body weight for 60 minutes. before glucose load.

In fig. 1 shows Table 1 - Results of a study of the hypoglycemic activity of the infusion of blue cyanosis herb, where: + - P <.05; ++- P<0.01, +++- P<0.001 - significance of differences when comparing between experimental and control indicators with initial values (fasting); * - P<0.05; ** - P<0.01, *** - P<0.001 - significance of differences when comparing between experimental and control indicators, ### - P<0.001 - reliability of differences when comparing between indicators of experimental groups.

Example 1

A method for producing a monocomponent oral hypoglycemic agent - an infusion of blue cyanosis herb.

To obtain the proposed monocomponent oral hypoglycemic agent, infusion of blue cyanosis herb, 10 g of air-dried plant material (blue cyanosis herb) with a moisture content of 11%, crushed to a particle size passing through a sieve with a particle size of 3 mm, is poured into 170 ml (taking into account the calculated water absorption coefficient equal to 1.7) purified water at room temperature, infused in an infusion apparatus in a boiling water bath with frequent stirring for 15 minutes, then cooled at room temperature for 45 minutes; filter, squeezing out the plant material, and add purified water to 100 ml. As a result, an infusion is obtained in a mass-volume ratio of 1:10, i.e. for 1 g of air-dried raw materials of blue cyanosis herb with a moisture content of 11%, use 10 ml of extractant - purified water, [State Pharmacopoeia of the Russian Federation: in 4 volumes, 14th ed. - Moscow. 2018. URL: http://femb.ru/femb/pharmacopea.php]. The dry residue of the infusion of blue cyanosis herb, obtained in accordance with the requirements of the State Fund of the Russian Federation [State Pharmacopoeia of the Russian Federation: in 4 volumes, 14th ed. - Moscow. 2018. URL: http://femb.ru/femb/pharmacopea.php] was 12 mg/ml.

An infusion of blue cyanosis herb, obtained by the standard method, is suitable for oral use to correct postprandial glycemia.

Results of preclinical studies of the effectiveness of infusion of blue cyanosis herb for the correction of postprandial glycemia.

A study of the effectiveness of the proposed monocomponent oral hypoglycemic agent - an infusion of blue cyanosis herb - for the correction of postprandial glycemia was carried out using a glucose tolerance test model in preclinical studies on laboratory animals. When conducting research, we took into account the recommendations of current guidelines for preclinical studies, incl. Guidelines for conducting preclinical studies of medicinal products [Guidelines for conducting preclinical studies of medicinal products. Part one [ed. A.N. Mironov]. - M.: Grif i K, 2012. - 944 p.]. The studies were carried out in compliance with the ethical principles of animal experiments, taking into account the requirements of the European Convention for the Protection of Vertebrate Animals. The glucose tolerance test was carried out in preclinical studies on healthy adult animals according to the well-known method [Experimental pharmacology - principles, models, analysis: monograph / A.V. Buzlama, V.A. Nikolaevsky, Yu.N. Chernov, A.I. Slivkin. - Voronezh: Publishing and Printing Center of Voronezh State University, 2013. - 362 pp.; Preclinical studies of medicinal substances: textbook. allowance / A.V. Buzlama [and others]; edited by A.A. Svistunova. - M.: GEOTAR-Media, 2017. - 384 p.]. The studies were conducted on 30 white outbred conventional male mice weighing 17-23 g, 3 groups, 10 animals each. Before the experiment, all animals were subjected to food deprivation for 12 hours with free access to water. Animals of the first experimental group were given a single dose orally through a gastric tube over 60 minutes. Before the introduction of glucose, an aqueous infusion of blue cyanosis herb was administered, prepared according to the method described above (see above). The animals of the second experimental group were administered a comparison drug, which was used as a well-known hypoglycemic drug of plant origin "Arfazetin", prepared in accordance with the instructions on the packaging [https://www.rlsnet.ru/drugs/arfazetin-e-24565], aqueous infusion of the collection with a mass-volume ratio of 1:10, i.e. For 1 g of the drug, 10 ml of extractant is used, the resulting infusion, for ease of administration of the required volume, was diluted with water 2 times and administered once orally over 60 minutes. before administering glucose through a gastric tube. The dose of both infusions from medicinal plant materials was calculated according to standard recommendations for dosing regimens for infusions, based on the recommended daily dose for humans. For the infusion of cyanosis herb, the recommended daily dose for a person (body weight 70 kg) is 1 glass of infusion 3 times a day, which, as a result of recalculation based on the body weight of the animal, amounted to 0.2 ml of infusion per 20 g of animal weight, recalculated based on dry residue (12 mg/ml), the dose was 120 mg/kg. For the infusion of Arfazetine (infusion 1:10 diluted with water 2 times), based on the dry residue (12 mg/ml) and the volume of 0.12 ml per 20 g of body weight, the dose was 72 mg/kg. The control group of healthy animals was administered distilled water in a volume of 0.2 ml per 20 g of body weight, once orally for 60 minutes. to glucose. After 60 min. After administration of the studied extracts from medicinal plant materials (infusion of blue cyanosis herb or infusion of the drug Arfazetin), all animals in the control and experimental groups were administered a single subcutaneous injection of 40% glucose solution at the rate of 3 g/kg. 30, 60, 120 minutes after the administration of glucose in animals of all groups, the glucose content in capillary blood was determined using a glucometer (Satellite Express, Russia). Blood sampling was performed by distal tail resection. The results were subjected to statistical processing using well-known methods of medical and biological statistics with the calculation of average values, errors of the average, assessment of the significance of differences was carried out using parametric tests (Student's t-test) and non-parametric tests (Wilcoxon test and Mann-Whitney U test).

The results of the study of the hypoglycemic activity of the blue cyanosis infusion are presented in Table 1 (Fig. 1).

It was found that in the control group (healthy animals), against the background of a glucose load, the maximum postprandial concentration of glucose in the blood was observed after 30 minutes. after the administration of glucose, amounting to 15.79 mmol/l, which is significantly 2.93 times higher than the initial level, then a decrease in glycemia occurs, so after 60 minutes. this figure is 1.72 times (or 72.1%) higher than the initial one, and by 120 min. glycemia reaches the initial normal values (5.21 mmol/l).

Against the background, the introduction of Arfazetin infusion after 30 minutes. glycemia was 12.5% lower than in the control group after 60 minutes. approached the values of the control group, being only 2.6% less than in the control after 120 minutes. no significant further decrease in glucose concentration was detected, glycemia was 70.4% higher than in the control and 65.1% higher than the initial level, which indicates the cessation of the hypoglycemic effect of the drug.

A pronounced hypoglycemic effect was revealed against the background of the administration of an infusion of blue cyanosis herb. So, after 30 minutes. after glucose administration, glycemia was 7.35 mmol/l, which was significantly 53.5% lower (or 2.1 times) than in the control group, 36% lower than the initial level and 46.8% lower than in a group of animals that were administered Arfazetine infusion. After 60 min. a decrease in glucose levels to initial values was detected (indicators correspond to normal values - 5.53 mmol/l), which is 40.3% lower (or 1.6 times) than in the control group and 38.7% lower compared with the group receiving Arfazetine. After 120 min. a significant decrease in glycemia was revealed by 33.2% (or 1.49 times) compared to the control group, which is 35.3% less than the initial level of glycemia and 60.8% less compared to the group of animals receiving Arfazetin.

Thus, in preclinical studies using a glucose tolerance test model, a fairly pronounced hypoglycemic effect of the blue cyanosis herb infusion was revealed with a single oral dose of 120 mg/kg, manifested by a decrease in postprandial glycemia at a glucose load of at least 1.5-2 times compared with control group, starting no later than 1.5 hours after administration of the infusion, lasting at least 2 hours and exceeding in severity the effect of the known hypoglycemic herbal drug Arfazetin by 1.5-2 times.

The data obtained indicate the effectiveness of the proposed method for correcting postprandial glycemia, implemented by using a monocomponent medicinal herbal preparation with hypoglycemic activity, and characterized in that an infusion of blue cyanosis herb is used as a monocomponent medicinal herbal preparation in a mass-volume ratio per 1 g of raw material with moisture content 11% - 10 ml of extractant - purified water, administered orally at a dose of 120 mg / kg (based on dry residue) for 60 minutes. before glucose load.

Claims (1)

A method for correcting postprandial glycemia, including the use of a monocomponent medicinal herbal preparation with hypoglycemic activity, characterized in that an aqueous infusion of blue cyanosis herb Polemonii caerulei herba is used as a monocomponent medicinal herbal preparation in the ratio of 1 g of air-dried plant material with a moisture content of 11% per 10 ml of extractant - purified water, the infusion is administered orally at a dose based on the dry residue of the infusion of 120 mg of the dry residue of the infusion / kg of body weight 60 minutes before the glucose load.

Images